SETH LERNER to Dasatinib
This is a "connection" page, showing publications SETH LERNER has written about Dasatinib.
Connection Strength
0.120
-
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urol Oncol. 2016 Jan; 34(1):4.e11-7.
Score: 0.103
-
Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Mol Cancer Ther. 2010 May; 9(5):1128-35.
Score: 0.018